Core Viewpoint - China National Pharmaceutical Group (01177.HK) announced that its subsidiary Beijing Tide Pharmaceutical Co., Ltd. has received clinical trial approval from the National Medical Products Administration (NMPA) for its innovative drug TRD221, a complement protein modulator intended for the treatment of osteoarthritis [1]. Group 1 - The drug TRD221 is classified as a national Class 1 innovative drug [1]. - The approval from NMPA marks a significant milestone for the company in its drug development pipeline [1]. - The intended use of TRD221 is specifically for osteoarthritis, indicating a focus on addressing this prevalent condition [1].

Core Viewpoint - China National Pharmaceutical Group's subsidiary, Beijing Tide Pharmaceutical Co., has received clinical trial approval from the NMPA for its first-in-class innovative drug TRD221, aimed at treating osteoarthritis [1][2]. Group 1: Company Developments - TRD221 is a complex polysaccharide drug developed in collaboration with the Chinese Academy of Medical Sciences, showcasing good biocompatibility and safety [1]. - The drug acts as a key protein regulator that inhibits the release of inflammatory factors from the complement system, thereby promoting cartilage repair and delaying disease progression [1]. Group 2: Industry Context - Osteoarthritis (OA) is a degenerative disease affecting joint cartilage, with approximately 595 million patients globally in 2020, expected to rise to 642 million by 2050 [2]. - The prevalence of primary OA among individuals over 40 in China has reached 46.3%, with an increasing trend due to an aging population [2]. - Current OA treatments primarily focus on pain relief, with significant unmet clinical needs in disease progression and joint function improvement [2]. - TRD221 has shown dual effects in animal models by alleviating pain symptoms and improving structural damage, indicating its potential as a new treatment option for OA [2].